PDB41 THE HANDLING OF GLUCOSE MONITORING AND INSULIN TREATMENT (HAGLUMIT) QUESTIONNAIRE CAPTURES HANDLING DIFFERENCES BETWEEN DIFFERENT SITUATIONS AND SYSTEMS FOR MONITORING BLOOD GLUCOSE IN DIABETES  by Mast, O & Schmidt, U
A104 Abstracts
PDB38
THE EFFECT OF WEIGHT CHANGES ON HEALTH-RELATED QUALITY
OF LIFE AND WORK IMPAIRMENT IN PATIENTS WITH TYPE 2 DIABETES
Krishnarajah G1, DiBonaventura M2, Wagner S3, Gupta S4
1Bristol-Myers Squibb, Princeton, NJ, USA, 2Consumer Health Sciences, new York, NY, USA, 
3Consumer Health Sciences International, Princeton, NJ, USA, 4Consumer Health Sciences, 
Princeton, NJ, USA
OBJECTIVES: To investigate whether patients with type-2 Diabetes Melittus (T2DM) 
who gained q5% of their bodyweight over the course of one year experienced changes 
in health-related quality of life (HRQoL) and work impairment relative to those who 
lost q5% of their bodyweight. METHODS: Data were taken from the 2006 and 2007 
National Health & Wellness Survey, an annual, cross-sectional, Internet survey of US
adults. All patients in survey with T2DM whose 2006–2007 weight gain was q5% of 
their bodyweight (n  300) were compared to those whose weight loss was q5% of 
their bodyweight (n  330) on levels of HRQoL (assessed with the SF-8 and SF-12
for 2006 and 2007, respectively) and levels of work impairment (assessed with the 
Work Productivity and Activity Impairment Questionnaire (WPAI)) in a series of 
multiple regressions, controlling for demographics, volitional weight loss (whether or
not respondents were taking steps to lose weight), and comorbidities. RESULTS: It 
was shown that weight gain was associated with signiﬁ cantly lower levels of the SF-12 
Physical Component Summary (mean score (M)  39.6 vs. M  41.5, p  0.01). Among
obese respondents, this effect was ampliﬁ ed (M  37.6 vs. M  40.3, p  0.01). No 
signiﬁ cant differences were found between T2DM patients who gained q5% of 
their weight and those who lost q5% of their weight on Mental Component Summary 
(M  48.6 vs. M  47.9, p  0.34), absenteeism (mean impairment (M)  4.6% vs. 
M  1.8%, p  0.32), presenteeism (M  18.9% vs. M  14.3%, p  0.26), total work 
impairment (M  20.1% vs. M  16.6%, p  0.46), or activity impairment (M 
33.8% vs. M  31.4%, p  0.22), though most effects were in the expected direction.
CONCLUSIONS: T2DM patients who gained weight, especially for obese individuals, 
reported signiﬁ cantly lower levels of HRQoL relative to those who lost weight. Treat-
ments that avoid weight gain and/or promote weight loss could have a beneﬁ cial
impact beyond HgbA1c for T2DM patients.
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OBJECTIVES: The Diabetes Utility Index (DUI) is a brief, self-administered diabetes-
speciﬁ c PBMH. We describe the development of the valuation function for the DUI 
and report its validity. METHODS: MAUT identiﬁ ed 20 of 768 DUI health states 
(anchor states, single-attribute level states, and marker states) for which preferences 
were then elicited via Visual Analog Scale and Standard Gamble (SG) tasks during 
personal interviews of individuals with diabetes recruited from primary care and com-
munity settings around Morgantown, WV. A valuation function calculating utilities 
for all DUI health states and attribute-level utilities was developed. A DUI validation 
survey was mailed in collaboration with the West Virginia University Diabetes Insti-
tute. Clinical data (ICD-9 codes and A1C values) and other self-reported data were 
merged with function-derived DUI utilities. RESULTS: Employing MAUT, a DUI valu-
ation function between 1.00  Perfect Health and 0.00  the all worse “Pits” state 
(adjusted to yield utilities between 1.00  Perfect Health and 0.00  Dead) was devel-
oped from data on 100 interviewees. A total of 396 persons with diabetes completed 
the validation survey (33% response). The DUI valuation function-derived utilities
compared favorably to cardinal SG utilities obtained directly on three DUI health 
states, but slightly underestimated SG utilities for mild and moderate health states 
(mean absolute difference  0.05). There was a small correlation between DUI utilities
and average A1C values (r  0.30, p  0.001). Respondents with two or more com-
plications had lower DUI utilities than those with none (p  0.001) or one complica-
tion (p  0.015). Insulin users had lower DUI utilities compared to non-users (p 
0.001), and those with A1C under 7 had higher DUI utilities than those with A1C of 
7 or greater (p  0.001). CONCLUSIONS: These results provide initial evidence of 
the DUIs feasibility and validity. Further research will demonstrate the generalizability
of these ﬁ ndings, show the responsiveness of the DUI, and report the clinical mean-
ingfulness of DUI change scores.
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OBJECTIVES: Hypoglycemia is a side-effect of treatment with oral anti-hyperglycemic
agents (OAHAs), especially sulfonylureas (SU). This study assessed the impact of 
self-reported hypoglycemia on health-related quality of life (HRQoL) among patients
with type-2 diabetes mellitus (T2DM), treated with OAHAs. METHODS: A cross-
sectional, internet-based study was conducted among 2008 participants from the US 
National Health and Wellness Survey 2007. Patients with self-reported T2DM treated
with OAHAs only were included. For each level of self-reported hypoglycemic severity
(mild, moderate, severe), frequency (1 to 2 episodes, 3 to 6 episodes, or  than once 
per month) data for six months prior to survey were collected. Very severe hypogly-
cemia (medical assistance required) was recorded as either one episode or  to two 
episodes. Utility was measured using the EQ-5D, and fear of hypoglycemia using the
Worry subscale of the Hypoglycemia Fear Survey II (HFS). RESULTS: Mean age was 
58 (o11) years, 43% were female, and 72.2% reported HbA1c goal attainment (7%). 
The proportions of patients on SU monotherapy, SU combination therapy, and other 
treatment regimens were 10.7%, 39.7%, and 49.6%, respectively. Hypoglycemic epi-
sodes were reported by 61.6% of patients (45.6% mild, 37.4% moderate, 13.2% 
severe and 3.8% very severe). After adjusting for age, gender, weight gain, microvas-
cular and macrovascular complications, the utility scores decreased by increasing 
severity and frequency of hypoglycemic episodes (with reference  no hypoglycemia), 
i.e., 0.008, 0.013, 0.015 for mild respectively, 0.046, 0.061, 0.11 for moderate, 0.089,
0.16, 0.27 for severe, and 0.17, 0.27 for very severe, whereas HFS scores increased, 
4.6, 5.5, 7.8 for mild, 11.4, 15.2, 13.8 for moderate, 15.5, 20.1, 25.5 for severe, and 
25.6, 26.6 for very severe. CONCLUSIONS: Self-reported hypoglycemia was experi-
enced by over half of the patients on OAHAs and was associated with reduced quality
of life. The magnitude of the reduction increased with frequency and severity of 
hypoglycemic episodes.
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OBJECTIVES: Evaluate difﬁ culties in handling Self Monitoring of Blood Glucose
(SMBG) from a patient’s perspective under normal and stressed conditions, using a 
new strip-free SMBG system. METHODS: The newly developed HaGluMIT question-
naire captures patient-reported ease of performing 9 typical steps in the SMBG process 
(7-point scale: 1 (very easy) to 7 (very difﬁ cult)). Fifty insulin treated diabetes patients
participating in a 2-week product evaluation study used the new Accu-Chek Mobile 
system in parallel to their current SMBG systems. They were asked to voluntarily ﬁ ll
out HaGluMIT at the beginning (current system) and the end (new system). RESULTS:
Thirty-six subjects completed both questionnaires and were eligible for comparative 
analysis (1 missing pre-evaluation and 13 missing post-evaluations). Mean SMBG
duration was 14 years with currently 5.7 tests per day. Twenty-three subjects were 
using an insulin pump. Data logging (2.68) was perceived to be most difﬁ cult to handle
under normal conditions followed by teststrip vials (2.44), lancets (2.26), carrycase
(2.10), teststrips (2.06), meter (1.97), blood application (1.94), lancet device (1.91) 
and insulin application (1.75). Under stressed conditions scores increased an average
of 0.68 points. Post-evaluations demonstrated statistically signiﬁ cant improvements 
for lancets, blood application and data logging under normal and stressed conditions 
in favor of the new system. The impact of stress was lower (average increase: 0.59 
points). CONCLUSIONS: A number of patient reported handling problems in per-
forming SMBG are reported in former research. This might result in skipping tests or 
making decisions based on inaccurate measures. Data logging is perceived to be most 
difﬁ cult to handle, followed by lancets, teststrips/vials and carrycase. HaGluMIT 
captures changes in handling difﬁ culty. Stress (e.g. from public attention, time pressure 
or hypoglycemic states) increases the difﬁ culty of handling. An integrated SMBG 
system without single strips and lancets signiﬁ cantly improved handling difﬁ culties
under normal and stressed conditions.
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OBJECTIVES: The objective was to understand how type-2 diabetes mellitus (T2DM) 
patients and their physicians perceive weight in relation to the objective measure
of body mass index (BMI). METHODS: Analysis was performed using data from 
the Adelphi Diabetes Disease Speciﬁ c Programme (DSP), a large cross-sectional 
study of clinical and treatment practice. Physicians (diabetologists and primary care 
practitioners) provided clinical assessment and information on T2DM patients. All
physicians and consenting patients were required, separately, to categorise patient 
weight as: normal, overweight, severely overweight/obese, severely obese. Physicians
also provided height and weight for patients but were not required to calculate BMI. 
Physician and patient estimates were subsequently compared with calculated BMI 
for each patient. RESULTS: A total of 132 (US) and 511 (5 EU countries) physicians
participated. Physicians categorised the weight of 928 (US) and 3969 (EU) T2DM 
patients for whom BMI was calculated. Equivalent matched numbers of patients 
categorising their weight was 626 (US) and 2013 (EU). Patient mean age was 62 years;
duration of T2DM 6 years; 51% were male; 55% in US and 33% in EU were 
obese (BMI / 30). Across all weights, some patients’ weight category was underes-
timated by their physicians (US 38% underestimated vs. 54% correct; EU 21% vs. 
69%). T2DM patients were more likely to underestimate their weight (US 60% 
underestimated vs. 37% correct, EU 43% vs. 51%). Discrepancies in weight estima-
tion were greatest for countries where overall mean BMI was 30 (US, UK) and least 
